Benitec Biopharma Inc.

NasdaqCM:BNTC Rapporto sulle azioni

Cap. di mercato: US$243.5m

Benitec Biopharma Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jerel Banks

Amministratore delegato

US$2.8m

Compenso totale

Percentuale dello stipendio del CEO22.4%
Mandato del CEO6.4yrs
Proprietà del CEOn/a
Durata media del management6.4yrs
Durata media del Consiglio di amministrazione9.1yrs

Aggiornamenti recenti sulla gestione

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Recent updates

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma prices of $18M securities offering

Sep 13

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Sep 02

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12
Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27
Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jerel Banks rispetto agli utili di Benitec Biopharma?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$21m

Jun 30 2024US$3mUS$628k

-US$22m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023n/an/a

-US$22m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023US$919kUS$540k

-US$20m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022n/an/a

-US$19m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022US$800kUS$506k

-US$18m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021n/an/a

-US$18m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021US$1mUS$440k

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020n/an/a

-US$11m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020US$632kUS$400k

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019n/an/a

-US$6m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019US$615kUS$400k

US$3m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

US$2m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018US$91kn/a

-US$9m

Compensazione vs Mercato: La retribuzione totale di Jerel ($USD 2.80M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.46M ).

Compensazione vs guadagni: La retribuzione di Jerel è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Jerel Banks (49 yo)

6.4yrs

Mandato

US$2,798,977

Compensazione

Dr. Jerel A. Banks, Ph D., M.D., has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks has been the Executive Chairman of the Board at Benitec Biopharma Inc. since O...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jerel Banks
Executive Chairman & CEO6.4yrsUS$2.80mNessun dato
Megan Boston
Executive Director6.4yrsUS$1.28m0.11%
$ 272.0k
Michael Graham
Head of Discovery & Founding Scientist9.4yrsUS$222.18kNessun dato
Claudia Kloth
Senior Vice President of Manufacturingno dataNessun datoNessun dato

6.4yrs

Durata media

Gestione esperta: Il team dirigenziale di BNTC è esperto e expertise (durata media dell'incarico 6.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Jerel Banks
Executive Chairman & CEO8.1yrsUS$2.80mNessun dato
Megan Boston
Executive Director8.3yrsUS$1.28m0.11%
$ 272.0k
J. Buchi
Independent Non-Executive Director11.6yrsUS$159.97k0.22%
$ 546.5k
Peter Francis
Independent Non-Executive Director18.8yrsUS$154.51k0.000080%
$ 194.8
Edward Smith
Independent Non-Executive Director4.6yrsUS$152.47k0%
$ 0
Kishan Mehta
Directorless than a yearNessun datoNessun dato
Geoffrey McCaughan
Member of Hepatology Clinical Advisory Board9.1yrsNessun datoNessun dato
Harry Janssen
Member of Hepatology Clinical Advisory Board9.1yrsNessun datoNessun dato
Keyur Patel
Member of Hepatology Clinical Advisory Board9.1yrsNessun datoNessun dato
George Dickson
Member of Scientific & Clinical Advisory Boardno dataNessun datoNessun dato

9.1yrs

Durata media

52.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BNTC sono considerati esperti (durata media dell'incarico 9.1 anni).